دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Issue Highlights page
doi : 10.1016/S0360-3016(21)02569-4
Volume 111, Issue 2, 1 October 2021, Pages A11-A12
Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer
ShariDamastMD*EmmaFieldsMD†ElizabethKiddMD*MatthewHarkenriderMD‡SupriyaChopraMD§JunzoChinoMD?
doi : 10.1016/j.ijrobp.2021.05.002
Volume 111, Issue 2, 1 October 2021, Pages 299-306
In the Hot Seat
Lachlan J.McDowellMB BS FRANZCR
doi : 10.1016/j.ijrobp.2018.02.163
Volume 111, Issue 2, 1 October 2021, Pages 307-308
Long Talk, Short RT
JuneCorryMD
doi : 10.1016/j.ijrobp.2018.07.005
Volume 111, Issue 2, 1 October 2021, Page 309
A Two-Headed Heated Debate
DavidRabenMD?AdamRabenMD†‡
doi : 10.1016/j.ijrobp.2018.08.041
Volume 111, Issue 2, 1 October 2021, Page 310
EXTREME-ly Hot
JulietteThariatMD, PhD
doi : 10.1016/j.ijrobp.2019.07.053
Volume 111, Issue 2, 1 October 2021, Page 311
Peas in the Pod: Systemic Therapy for Systemic Disease, Radiation for Local Disease
William M.MendenhallMD
doi : 10.1016/j.ijrobp.2021.05.127
Volume 111, Issue 2, 1 October 2021, Page 311
Can Sex and Seniority Predict the Quality of a Journal Reviewer's Manuscript Critique?
Daniel S.JamoraboMD*Matthew P.DeekMD†Sue S.YomMD‡HasanRehmanMD§Anthony L.ZietmanMD?Sabin B.MotwaniMD¶William M.BriggsPhD#SinaeKimPhD??Daniel T.ChangMD††Salma K.JabbourMD‡‡
doi : 10.1016/j.ijrobp.2021.05.111
Volume 111, Issue 2, 1 October 2021, Pages 312-316
Reasons for Declining Applicant Numbers in Radiation Oncology From the Applicants' Perspective: Results From the Applicant Concerns and Radiation Oncology Sources Survey (ACROSS)
Jared AlexanderMaasMD*Omer LeeBurnettIIIMD†Samuel RayMarcromMD?
doi : 10.1016/j.ijrobp.2021.05.007
Volume 111, Issue 2, 1 October 2021, Pages 317-327
Applications to radiation oncology in the United States have decreased the past 3 years, resulting in unfilled residency positions (30 [14.5%] in 2019 and 35 [18.5%] in 2020). The aim of this study is to understand the concerns among radiation oncology applicants and whether these concerns may have led to a decline in applications.
Navigating Past the Chaos of the Radiation Oncology 2021 Match
Emma C.FieldsMD*Brian D.KavanaghMD/MPH†
doi : 10.1016/j.ijrobp.2021.06.015
Volume 111, Issue 2, 1 October 2021, Pages 328-330
Differential Impact of COVID-19 on Cancer Diagnostic Services Based on Body Regions: A Public Facility-Based Study in Hong Kong
VarutVardhanabhutiMBBS, PhDKei ShingNgPhD
doi : 10.1016/j.ijrobp.2021.05.010
Volume 111, Issue 2, 1 October 2021, Pages 331-336
Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee
Robert W.MutterMD*J. IsabelleChoiMD†Rachel B.JimenezMD‡Youlia M.KirovaMD§MarcioFagundesMD||Bruce G.HafftyMD¶Richard A.AmosMSc, FIPEM#Julie A.BradleyMD??Peter Y.ChenMD††XuanfengDingPhD††Antoinette M.Carr††Leslie M.TaylorBSN, RN††MarkPankuchPhD‡‡Raymond B. MailhotVegaMD, MPH??Alice Y.HoMD†Petra WittNyströmMD, PhD§§Lisa A.McGeeMD||||James J.UrbanicMD¶¶OrenCahlonMD##John H.MaduroMD, PhD???Shannon M.MacDonaldMD‡
doi : 10.1016/j.ijrobp.2021.05.110
Volume 111, Issue 2, 1 October 2021, Pages 337-359
Radiation therapy plays an important role in the multidisciplinary management of breast cancer. Recent years have seen improvements in breast cancer survival and a greater appreciation of potential long-term morbidity associated with the dose and volume of irradiated organs. Proton therapy reduces the dose to nontarget structures while optimizing target coverage. However, there remain additional financial costs associated with proton therapy, despite reductions over time, and studies have yet to demonstrate that protons improve upon the treatment outcomes achieved with photon radiation therapy. There remains considerable heterogeneity in proton patient selection and techniques, and the rapid technological advances in the field have the potential to affect evidence evaluation, given the long latency period for breast cancer radiation therapy recurrence and late effects. In this consensus statement, we assess the data available to the radiation oncology community of proton therapy for breast cancer, provide expert consensus recommendations on indications and technique, and highlight ongoing trials’ cost-effectiveness analyses and key areas for future research.
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation
Julius K.WengMD*XiudongLeiPhD*PamelaSchlembachMD*Elizabeth S.BloomMD*Simona F.ShaitelmanMD, Med*Isidora Y.ArzuMD, PhD*GregoryChronowskiMD*TomasDvorakMD†EmilyGradeMD‡KarenHoffmanMD, MPH*GeorgePerkinsMD, MBA*Valerie K.ReedMD*Shalin J.ShahMD*Michael C.StauderMD*Eric A.StromMD*WelelaTereffeMD*Wendy A.WoodwardMD, PhD*Gabriel N.HortobagyiMD*Kelly K.HuntMD*Thomas A.BuchholzMD§Benjamin D.SmithMD*
doi : 10.1016/j.ijrobp.2021.05.004
Volume 111, Issue 2, 1 October 2021, Pages 360-370
Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials
RajSinghMD*Eric J.LehrerMD, MS†MingWangMS, PhD‡Haley K.PerlowMD§Nicholas G.ZaorskyMD MS‡||Daniel M.TrifilettiMD¶JosephBoviMD#PierinaNavarriaMD??SilviaScocciantiMD††VinaiGondiMD‡‡Paul D.BrownMD§§Joshua D.PalmerMD||||*
doi : 10.1016/j.ijrobp.2021.05.001
Volume 111, Issue 2, 1 October 2021, Pages 371-384
Prognostic Importance of MRI-Detected Extramural Venous Invasion in Rectal Cancer: A Literature Review and Systematic Meta-Analysis
Jessica JulianaTanMBChB, MRCS?†Rachel V.CartenMBBS, MRCS?†AmnaBabikerMBChB?MutiAbulafiMS (Lon)†Amy C.LordMBChB, FRCS?GinaBrownMD?
doi : 10.1016/j.ijrobp.2021.05.136
Volume 111, Issue 2, 1 October 2021, Pages 385-394
The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis
Won IckChangMD*Byoung HyuckKimMD, PhD†Hyun-CheolKangMD, PhD*KyuboKimMD, PhD‡Kyung-HunLeeMD, PhD§Do-YounOhMD, PhD§HongbeomKimMD, PhD||WooilKwonMD, PhD||Jin-YoungJangMD, PhD||Eui KyuChieMD, PhD*¶
doi : 10.1016/j.ijrobp.2021.05.012
Volume 111, Issue 2, 1 October 2021, Pages 395-404
Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review
YingLiMM*HanshanLiuMM†ChaoSunMM‡XudongYinMM*JiandongTongMM*XizhiZhangMM§XiaolinWangMD‡XinYuanMM*ZhengrongZhangMM*GuangyuLuPhD?YixunGuMM*YongpengLiMM¶TianyuHuangMM*ZheQiaoMM¶YongChenMD*
doi : 10.1016/j.ijrobp.2021.04.031
Volume 111, Issue 2, 1 October 2021, Pages 405-416
Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer
KajananNithiyananthan?NicolaCreightonMAppStat†DavidCurrowPhD†Jarad M.MartinPhD*‡
doi : 10.1016/j.ijrobp.2021.04.033
Volume 111, Issue 2, 1 October 2021, Pages 417-423
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial
BoQiuMD*†‡§?QiWenLiMD*†‡§?JunLingLiuMD†‡?¶YanHuangMD†‡?QingSongPangMD#ZhengFeiZhuMD??XiYangMD??BinWangPhD*†‡LiChenPhD*†‡JianLanFangMS*†‡MaoShengLinMS*†‡XiaoBoJiangMS*†‡SuPingGuoMS*†‡JinYuGuoBS*†‡DaQuanWangMD*†‡FangJieLiuMD*†‡ChuChuMD*†‡XiaoYanHuangPhD*†‡ChuanMiaoXieMD†‡††HuiLiuMD*†‡§?
doi : 10.1016/j.ijrobp.2021.05.003
Volume 111, Issue 2, 1 October 2021, Pages 424-435
Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer
Gregory M.M.VideticMDCM, FRCPC, FACR, FASTROChandana A.ReddyMSNeil M.WoodyMDKevin L.StephansMD
doi : 10.1016/j.ijrobp.2021.05.116
Volume 111, Issue 2, 1 October 2021, Pages 436-442
Computed Tomography-Based Delta-Radiomics Analysis for Discriminating Radiation Pneumonitis in Patients With Esophageal Cancer After Radiation Therapy
LuWangMD?†ZhenhuaGaoMD†ChengmingLiMD†LiangchaoSunMD†JianingLiBS†JinmingYuMD?†XueMengMD†
doi : 10.1016/j.ijrobp.2021.04.047
Volume 111, Issue 2, 1 October 2021, Pages 443-455
Patient-Reported Toxicity and Quality-of-Life Profiles in Patients With Head and Neck Cancer Treated With Definitive Radiation Therapy or Chemoradiation
LisaVan den BoschMD?Hans Paulvan der LaanPhD*Arjenvan der SchaafPhD*Sjoukje F.OostingPhD†Gyorgy B.HalmosPhD‡Max J.H.WitjesPhD§EdwinOldehinkelMD*Tineke W.H.MeijerPhD*Johanna G.M.van den HoekMD*Roel J.H.M.SteenbakkersPhD*Johannes A.LangendijkPhD*
doi : 10.1016/j.ijrobp.2021.05.114
Volume 111, Issue 2, 1 October 2021, Pages 456-467
External Beam Radiation Therapy in pT4 Well-Differentiated Thyroid Cancer: A Population-Based Study of 405 Patients
DaeganSitMD*†‡Wan XianKohBSc‡AriaShokoohiBSc†TylerRaycraftBSc‡MitchellVuMD‡JeremyHammBSc†EricTranMD?†EricBertheletMD*†JonnWuMD*†RobertOlsonMD*§?Sarah NicoleHamiltonMD*†
doi : 10.1016/j.ijrobp.2021.05.006
Volume 111, Issue 2, 1 October 2021, Pages 468-478
Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation
LinanSongMD?†ShuoWangMD?TongFangBS†XiaoguangQiuBS‡XiaoliWangMD?XinnaZhouMS?Michael A.MorseMD§AmyHobeikaPhD§WanshuiWuMD?HuabingYangBS?JunRenMD, PhD?§Herbert KimLyerlyMD§
doi : 10.1016/j.ijrobp.2021.04.041
Volume 111, Issue 2, 1 October 2021, Pages 479-490
ALKBH5-Modified HMGB1-STING Activation Contributes to Radiation Induced Liver Disease via Innate Immune Response
GenwenChenMD1QianqianZhaoPhD1BaoyingYuanPhDBiaoWangMDYangZhangMDZongjuanLiPhDShisuoDuPhDZhaochongZengPhD
doi : 10.1016/j.ijrobp.2021.05.115
Volume 111, Issue 2, 1 October 2021, Pages 491-501
Radiation therapy, which is vital for the treatment of primary liver cancer, comes with unavoidable liver injury, which limits its implementation. N6-methyladenosine (m6A) methylation is involved in many molecular functions. However, its role in radiation-induced liver diseases (RILD) remains unknown. Herein, we investigate the role of m6A methylation in RILD.
Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses
JosephSiaMB ChB, FRANZCR, PhD*†‡JimHagekyriakouPhD§IoanaChindrisHSc*†HassanAlbarakatiMSc§TrevorLeongMBBS, MD, FRANZCR†‡RamonaSchlenkerPhD||Simon P.KeamPhD†¶#Scott G.WilliamsMBBS, BScMed, FRANZCR, MD‡Paul J.NeesonPhD†#Ricky W.JohnstonePhD, FAHMS*†Nicole M.HaynesPhD*†
doi : 10.1016/j.ijrobp.2021.05.014
Volume 111, Issue 2, 1 October 2021, Pages 502-514
Developing a Peptide That Inhibits DNA Repair by Blocking the Binding of Artemis and DNA Ligase IV to Enhance Tumor Radiosensitivity
ChuZhuPhDaXuanxuanWangMDabPingLiMDaYanhongZhuMDaYikanSunMDcJiamiaoHuBDaHaiLiuPhDaXiaonanSunPhDa
doi : 10.1016/j.ijrobp.2021.05.120
Volume 111, Issue 2, 1 October 2021, Pages 515-527
Effects of Single-Dose Versus Hypofractionated Focused Radiation on Vertebral Body Structure and Biomechanical Integrity: Development of a Rabbit Radiation-Induced Vertebral Compression Fracture Model
AlexanderPerdomo-PantojaMD*ChristinaHolmesPhD†Ioan A.LinaMD‡Jason A.LiauwMD*VarunPuvanesarajahMD§Brian C.GohMD, PhD?Chukwuebuka C.AchebeBS¶EthanCottrillMS*Benjamin D.ElderMD, PhD#Warren L.GraysonPhD¶Kristin J.RedmondMD, MPH??Soojung C.HurPhD††Timothy F.WithamMD*
doi : 10.1016/j.ijrobp.2021.04.050
Volume 111, Issue 2, 1 October 2021, Pages 528-538
Strategies for Motion Robust Proton Therapy With Pencil Beam Scanning for Esophageal Cancer
Ditte SlothMøllerPhD*Per RugaardPoulsenProf.†‡AndreasHagnerMSc?MathieuDufourMSc§MarianneNordsmarkAssoc. Prof.†Tine BisballeNyengMSc†Hanna RahbekMortensenPhD‡Christina MariaLutzPhD?LoneHoffmannPhD*
doi : 10.1016/j.ijrobp.2021.04.040
Volume 111, Issue 2, 1 October 2021, Pages 539-548
Normal Tissue Complication Probability (NTCP) Prediction Model for Osteoradionecrosis of the Mandible in Patients With Head and Neck Cancer After Radiation Therapy: Large-Scale Observational Cohort
Lisanne V.van DijkPhD*†Abdelrahman A.AbusaifMD*JillianRigertDMD, MD*Mohamed A.NaserPhD*Katherine A.HutchesonMD, PhD*‡Stephen Y.LaiMD, PhD*‡Clifton D.FullerMD, PhD*Abdallah S.R.MohamedMD*on behalf on the MD Anderson Symptom Working Group
doi : 10.1016/j.ijrobp.2021.04.042
Volume 111, Issue 2, 1 October 2021, Pages 549-558
Joint Optimization of Photon–Carbon Ion Treatments for Glioblastoma
Amit Ben AntonyBennanMSc*†‡JanUnkelbach§NiklasWahl?‡PatrickSalomeMSc†?MarkBangert?
doi : 10.1016/j.ijrobp.2021.05.126
Volume 111, Issue 2, 1 October 2021, Pages 559-572
In Regard to Marshall et al.
Edward C.HalperinMD, MA
doi : 10.1016/j.ijrobp.2021.05.119
Volume 111, Issue 2, 1 October 2021, Page 573
In Reply to Halperin
Deborah C.MarshallMD
doi : 10.1016/j.ijrobp.2021.05.118
Volume 111, Issue 2, 1 October 2021, Pages 573-574
In Regard to Shuryak et al.
James S.WelshMS, MDJoeBevelacquaPhDS.M.J.MortazaviPhDBillSacksMD, PhD
doi : 10.1016/j.ijrobp.2021.05.117
Volume 111, Issue 2, 1 October 2021, Pages 574-576
In Reply to Welsh et al.
IgorShuryakMD, PhDLisa A.KachnicMD, PhDDavid J.BrennerPhD, DSc
doi : 10.1016/j.ijrobp.2021.05.121
Volume 111, Issue 2, 1 October 2021, Pages 576-577
In Regard to Small et al.
AbdullaAl-RashdanMD
doi : 10.1016/j.ijrobp.2021.05.129
Volume 111, Issue 2, 1 October 2021, Pages 577-578
In Reply to Al-Rashdan
WilliamSmallJrMD, FACRO, FACR, FASTROLynne I.WagnerPhDDeborah WatkinsBrunerRN, PhD, FAAN
doi : 10.1016/j.ijrobp.2021.05.130
Volume 111, Issue 2, 1 October 2021, Page 578
In Regard to Ying Li et al.
RonaldChowMS, FRSPHCharles B.SimoneIIMD, FACRO
doi : 10.1016/j.ijrobp.2021.06.008
Volume 111, Issue 2, 1 October 2021, Page 579
In Reply to Chow and Simone
XinYuanMMYingLiMMXudongYinMMJiandongTongMMZhengrongZhangMMRuiWangMMYongChenMD
doi : 10.1016/j.ijrobp.2021.06.006
Volume 111, Issue 2, 1 October 2021, Page 580
In Regard to Ying Li et al.
TaoWangMMGuangyuTianMMXiaojunChenMM
doi : 10.1016/j.ijrobp.2021.06.004
Volume 111, Issue 2, 1 October 2021, Page 581
In Reply to Wang et al.
XudongYinMMYingLiMMJiandongTongMMYongChenMD
doi : 10.1016/j.ijrobp.2021.05.137
Volume 111, Issue 2, 1 October 2021, Page 582
In Regard to Frankart et al.
Pierre-AntoineLaurentMDKantaKaMDBertrandGachotMD, PhDQuitteriede KerangalMDPierreDescolsDMDJean-JacquesBrauDMDPierreBlanchardMD, PhDNadiaBenmoussaMD, PhD
doi : 10.1016/j.ijrobp.2021.06.005
Volume 111, Issue 2, 1 October 2021, Pages 582-584
In Reply to Laurent et al.
Andrew J.FrankartMDVinitaTakiarMD, PhD
doi : 10.1016/j.ijrobp.2021.06.007
Volume 111, Issue 2, 1 October 2021, Page 584
In Regard to Dinh et al.
SanthanamSundarMRCP, FRCRPaulSymondsMD, FRCR
doi : 10.1016/j.ijrobp.2021.05.008
Volume 111, Issue 2, 1 October 2021, Page 585
Erratum to: Redler G, Pearson E, Liu X, et al. Small Animal IMRT Using 3D-Printed Compensators. Int J Radiat Oncol Biol Phys 2021; 110(2):551-565.
doi : 10.1016/j.ijrobp.2021.06.011
Volume 111, Issue 2, 1 October 2021, Page 586
Erratum to: Khan B, Wang et al. Multicellular Spheroids as In Vitro Models of Oxygen Depletion During FLASH Irradiation. Int J Radiat Oncol Biol Ph 2021
doi : 10.1016/j.ijrobp.2021.06.010
Volume 111, Issue 2, 1 October 2021, Page 586
Erratum to: Li T-C, Liu C-C, Lee YZ, et al. Combination Therapy of Pulsed-Wave Ultrasound Hyperthermia and Immunostimulant OK-432 Enhances Systemic Antitumor Immunity for Cancer Treatment. Int J Radiat Oncol Biol Phys 2020; 108(1):140-149.
doi : 10.1016/j.ijrobp.2021.06.017
Volume 111, Issue 2, 1 October 2021, Page 586
Erratum to: Walshaw RC, Hoskin PJ, Choudhury A. Can Hypofractionation and Immune Modulation Coexist? Int J Radiat Oncol Biol Phys 2021;110(3):742–744.
doi : 10.1016/j.ijrobp.2021.06.003
Volume 111, Issue 2, 1 October 2021, Page 587
